Search

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

Highlights from the SWG

EHA2023 CongressThe EHA2023 Congress was held in Frankfurt, Germany, in June 2023. Guideline sessionTitle‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

Chairs and Members

ChairProf Dr Carlo Dufour, Gaslini Children’s Research Hospital, Genova (Italy)

Co-chairProf Dr Helen Papadaki, Institution University Hospital of Heraklion, Heraklion, Crete (Greece)

SWG Executive Board members
Kim De Keersmaecker, University of Leuven (Belgium)
Francesca Fioredda, G.

Read more

Publications

Autoimmune Neutropenias: Update on Clinical and Biological Features in Children and Adults
Fioredda, Francesca et al. HemaSphere vol. 7,1 e814. Jan. 2023.

Read more

Publications

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott…

Read more

Highlights from the SWG

The SWG organized a EHA scientific workshop entitled: “Shaping the future of MSC Therapy” in Amsterdam from November 23-25, 2017.

Read more

Chairs and Members

Chair and affiliation:
Willem E.

Read more

Highlights from the SWG

Standards for functional precision medicine projectStandards for functional precision medicine, a project initiated by EHA's SWG on Precision Hematology, received a 2023 SWG Grant and is currently underway.

Read more

SWG Educational Activities

During the annual meeting of EHA, a scientific session was organized: “Mesenchymal stromal cells: guardians of tissue homeostasis”.

Read more

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Read more